37.Bille, j. New nonculture-based methods for the diagnosis of invasive candidiasis / j.

Bille // Journal Current Opinion in Critical Care. – 2010. – Vol.16. – P. 460–464.

38.Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates / J. A. Ferreira, J. H. Carr, C. E. Starling, et al. // International Journal of Antimicrobial Agents and Chemotherapy. – 2009. – Vol. 53. – P. 4377–

4384.

39.Blot, S. Is Candida really a threat in the ICU? / S. Blot, G. Dimopoulos, J. Rello, et al. // Journal Current Opinion in Critical Care. – 2008. – Vol. 14. – P. 600–604.

40.Blot, S. I. Estimating attributable mortality of candidemia: clinical judgment vs. matched cohort studies. Eur. / Blot, S. I., K. H. Vandewoude. // Journal of Clinical Microbiology Infectious. – 2003. – Vol. 22. – Р. 132–133.

41.Blot, s. Management of invasive candidiasis in critically ill patients / s. Blot, k.

Vandewoude // Journal Drugs. – 2004. – Vol.64. – P. 2159–2175.

42.Bouza, e. Epidemiology of candidemia in intensive care units / e. Bouza, p. Muñoz

// International Journal of Antimicrobial Agents. – 2008. – Vol. 32. – Suppl. 2. – P.

87–91.

43.Brazilian Network Candidemia Study Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers / A. L. Colombo, M. Nucci, B. J. Park, et al. // Journal of Clinical Microbiology. – 2006. – Vol. 44. – Suppl. 8. – P. 2816–2823.

N. et al. // Science Translational Medicine. – 2012. – Vol. 4. - Issue 165. http//www.ScienceTranslationalMedicine.org 19 /165rv13

45.Cafingerprinting of Candida albicans isolates from human immunodeficiency virus- positive and healthy individuals reveals a new clade in South Africa. / E. Blignaut, C. Pujol, S. Lockhart, S. Joly, D. R. Soll // Journal of Clinical Microbiology. –

2002. – Vol. 40. – Р. 826–836.

46.Calderone, R. A. Virulence factors of Candida albicans / R. A. Calderone, W. A.

Fonzi // Journal Trends in Microbiology. – 2001. – Vol. 9. – Suppl. 7. – P. 327–335.

47.Candida albicans biofilm formation on soft denture liners and efficacy of cleaning protocols / S. Hahnel, M. Rosentritt, R. Burgers, G. Handel, R. Lang // Journal Gerodontology. – 2012. – Vol. 29. – Suppl. 2. – Р. 383–391.

48.Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome / G. Dimopoulos, F. Ntziora, G. Rachiotis, et al. // Journal Anesthesia and Analgesia. – 2008. - Vol. 106. – P.523-

529.

49.Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study / D. H. Kett, E. Azoulay, P. M. Echeverria, et al. // Journal Critical Care Medicine. – 2011. – Vol. 39. – P. 665–670.

50.Candida albicans tricuspid and pulmonic valve endocarditis: Challenge of relapsing risk and role of combined medical treatment and surgery/ Suheil Andreas Salamon, Kurt Fuursted, Henrik Egeblad, Eskild Petersen, Peter Ott // Scandinavian Journal of Infectious Diseases. – 2007. – Vol. 39. – Suppl. 6–7. – P. 641–644.

51.Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. / G. Dimopoulos, F. Ntziora, G. Rachiotis, A. Armaganidis, M. E. Falagas // Journal Anesthesia and Analgesia. –

2008. – Vol. 106. – Suppl. 2. – P. 523–529.

52.Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non- ICU settings in the SENTRY antimicrobial surveillance program / M. A. Pfaller, S.

A. Messer, G. J. Moet, R. N. Jones, M. Castanheira // International Journal of

Antimicrobial Agents. – 2011. – Vol. 38. – Suppl. 1. – P. 65–69.

53.Candida bloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY antimicrobial surveillance program, 2008–2009 / M. A. Pfaller, G. J. Moet, S. A. Messer, R. N. Jones, M. Castenheire // Journal of Antimicrobial Agents and Chemotherapy. – 2011. – Vol. 55. – Suppl. 2. – P. 561–566.

54.Candida parapsilosis meningitis as the first manifestation of AIDS: case report / J. J.

Sidrim, L. V. Perdigão–Neto , R. A. Cordeiro , et al. // Journal of Clinical

Microbiology. – 2011. – Vol. 60. – Suppl. 10. – Р. 1530–1533.

55.Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) / C. Viscoli, C. Girmenia, A. Marinus, et al. // World Journal of Clinical Infectious Diseases. – 1999. – Vol. 28. – Suppl. 5. – P.

1071–1079.

56.Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida. spp / G. E. Playford, D. Marriott, Q. Nguyen, et al. // Critical Care Medicine. – 2008. – Vol. 36. – Suppl. 7. – P. 2034–2039.

57.Candida colonization and subsequent infections in critically ill surgical patients / D.

Pittet, M. Monod, P. M. Suter, et al. // American Journal of Surgery. – 1994. – Vol.

220. – P. 751–758.

58.Candida spp colonization significance in critically ill medical patients: A prospective study. / P. E. Charles, F. Dalle, H. Aube, et al. // Journal of Intensive Care Medicine. – 2005. – Vol. 31. – Suppl. 3. – P. 393–400.

59.Candida parapsilosis, an emerging fungal pathogen. / D. Trofa, A. Gácser, J. D.

Nosanchuk // Journal of Clinical Microbiology Reviews. – 2008. – Vol. 21. – Р.

606–625.

60.Candida spp. with acquired echinocandin resistance, France, 2004–2010 / E.

Dannaoui, M. Desnos-Ollivier, D. Garcia-Hermoso, et al. // Journal Emerging

Infectious Diseases. – 2008. – Vol.18. – P. 86–90.

61.Candida urinary tract infection and Candida species susceptibilities to antifungal agents / K. Osawa, K. Shigemura, H. Yoshida, M. Fujisawa, S. Arakawa // The Journal of antibiotics. – 2013. – Vol. 66. – Suppl. 11. – Р. 651– 654.

62.Candidemia as a cause of septic shock and multiple organ failure in nonimmuno- compromised patients / S. Hadley, W. W. Lee, R. Ruthazer, S. A. Nasraway. // Journal of Critical Care Medicine. – 2002. – Vol. 30. – Р. 1808–1814

63.Candidaemia in a European paediatric university hospital: a 10-year observational study/ A. Tragiannidis, W. Fegeler, G. Rellensman, et al. // Journal of Clinical Mi- crobiology and Infection. – 2012. – Vol. 18. – Suppl. 2. – P. 27–30.

64.Candidemia in Europe: epidemiology and resistance / A. M. Tortorano, C. Kibbler, J. Peman, H. Bernhardt, L. Klingspor, R. Grillot // International Journal of Antimi- crobial Agents. – 2006. – Vol. 27. – Suppl. 5. – P. 359–366.

65.Candidemia in Finland, 1995–1999. / E. Poikonen, O. Lyytikäinen, V. J. Anttila, P.

Ruutu // Emerg Infect Dis. – 2003. – Vol. 9. – Suppl. 8. – P. 985–990.

66.Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. / E. G. Playford, D. Marriott, Q. Nguyen, et al. // Journal Critical Care Medicine. – 2008. – Vol. 36. – P. 2034–2039.

67.Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection / N. V. Sipsas, R. E. Lewis, J. Tarrand, et al. // The Cancer Journal. – 2009. – Vol. 115. – Suppl. 20. – P. 4745–4752.

68.Candiaemia in Sweden: a nationwide prospective observational survey / J. Ericsson, E. Chryssanthou, L. Klingspor, et al. // World Journal of Clinical Infectious Diseases. – 2013. – Vol. 19. – Suppl. 4. – P. 218–221.

69.Candidosis in the intensive care unit: a 20-year survey / A. M. Tortorano, L.

Caspani, A. L. Rigoni, E. Biraghi, A. Sicignano, M. A. Viviani // Jornal of Hospital

Infection. – 2004. – Vol. 57. – Suppl. 1. – P. 8–13.

70.CandiRea Study Group Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and

outcome / M. E. Bougnoux, G. Kac, P. Aegerter, C. d’Enfert, J. Y. Fagon // Journal of Intensive Care Medicine. – 2008. – Vol. 34. – Suppl. 2. – P. 292–299.

71.Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients / L. Senn, P. Eggimann, R. Ksontini, et al. // Journal of Intensive Care Medicine. – 2009. – Vol. 35. – P. 903–908.

72.Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011 / A. A. Cleveland, M. M. Farley, L. H. Harrison, et al. // World Journal of Clinical Infectious Diseases. – 2012. – Vol. 55. – Suppl. 10. – P. 1352–1361.

73.China-SCAN Team Invasive candidiasis in intensive care units in China: a multicentre prospective observational study / F. Guo, Y. Yang, Y. Kang, et al.

// Journal of Antimicrobial Chemotherapy. – 2013. – Vol. 68. – Suppl. 7. – P. 1660–

1668.

74.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America / P. G. Pappas, C. A. Kauffman, D. Andes, et al. // World Journal of Clinical Infectious Diseases. – 2009. – Vol. 48. – P. 503–

535.

75.Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species / B. Sendid, J. L. Poirot, M. Tabouret, et al. // Journal of Clinical Microbiology. – 2002.

– Vol. 51. – P. 433–442.

76.Comparative impact of hospital-acquired infections on medical costs, length of hos- pital stay and outcome between community hospitals and medical centers. / W. H. Sheng, J. T. Wang, D. C. T. Lu, W. C. Chie, Y. C. Chen, S. C. Chang. // Journal of Hospital Infection. – 2005. – Vol. 59. – Р. 205–214.

77.Cruciani, M. Management of Candida infections in the adult intensive care unit / M.

Cruciani, G. Serpelloni // Journal of Expert Opinion on Pharmacotherapy. – 2008. –

Vol. 9. – P. 175–191.

during sepsis using polymerase chain reaction-based pathogen detection / P. M. Dark, P. Dean, G. Warhurst // Journal of Critical Care. – 2009. – Vol. 13. – P. 217.

79.Demertzis, J. State of the art: imaging of renal infections. / J. Demertzis, C. O.

Menias. // Journal Emergency Radiology. – 2007. – Vol. 14. – Р. 13–22.

80.DiDone, L. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms. / L. DiDone, D. Oga, D. J. Krysan // Journal Yeast. – 2011. – Vol. 28. – Suppl. 8. – P. 561–568.

81.Diekema, D. J. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. / D. J. Diekema., M. A. Pfaller. // Journal Infection Control and Hospital Epidemiology. – 2004. – Vol. 25. – Р. 624–626.

82.Dimopoulos, G. A 10–year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece / G. Dimopoulos, A. Velegraki, M. E. Falagas // Journal of Antimicrobial Agents and Chemotherapy. – 2009. – Vol. 53. – P. 1242–1244.

83.Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non- albicans candidemia / A. F. Shorr, D. R. Lazarus, J. H. Sherner, et al. // Journal of Critical Care Medicine. – 2007. – Vol. 35. – P. 1077– 083.

84.Dr Mario Venditti Clinical Aspects of Invasive Candidiasis // – 2009. – Vol. 69. –

Suppl. 1. – Р. 39–43.

85.Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1–N3)-beta-D-glucan assay, Candida score, and colonization index / B. Posteraro, G. De Pascale, M. Tumbarello, et al. // Journal of Critical Care Medicine. – 2011. – Vol. 15. – 249 p.

86.Early treatment of candidemia in adults: a review / L. Ostrosky-Zeichner, B. J.

Kullberg, E. J. Bow, et al. // Med. Mycol. – 2011. – Vol. 49. – P. 113–120.

87.Economic impact of Candida colonization and Candida infection in the critically ill patient. / P. M. Olaechea, M. Palomar, C. Leon-Gil, et al. // European Journal of Clinical Microbiology & Infectious Diseases. – 2004. – P. 23–30.

// European Journal of Clinical Microbiology & Infectious Diseases. – 2004. – Vol.

23. – Suppl. 4. –P. 317–322.

89.Effects of nosocomial candidemia on outcomes of critically ill patients. / S. I. Blot, K. H. Vandewoude, E. A. Hoste, F. A. Colardyn. // The American Journal of Medi- cine. – 2002. – Vol. 113. – Р. 480–485.

90.Ellis, M. New dosing strategies for liposomal amphotericin B in highrisk patients / M. Ellis // Journal of Clinical Microbiology and Infection. – 2008. – Vol. 14. – Suppl. 4. – P. 55–64.

91.Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial / M. G. Schuster, J. E. Edwards Jr., J. D. Sobel, et al. // Journal of Annals of Internal Medicine. – 2008. – Vol. 149. – P. 83–90.

92.Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes / A. Lingappan, C. C. Wykoff, T. A. Albini, D. Miller, A. Pathengay, J. L. Davis, et al. //American Journal of Ophthalmology. – Vol. 153.

– Suppl. 1. – 2012. – Р. 162–166.

93.Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme / M. C. Arendrup, E. Dzajic, R. H. Jensen, et al. // Journal of Clinical Microbiology and Infection. – 2013. – Vol. 19. – Suppl. 8. – P. 343–353.

94.Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: Results from a surveillance study on fungaemia in Germany from July 2004 to August 2005 / M. Borg–von Zepelin, L. Kunz, R. Rüchel, U. Reichard, M. Weig, U. Gross // Journal of Antimicrobial Chemotherapy. – 2007. – Vol. 60. – Suppl. 2. – P. 424–428.

95.Epidemiology and antifungal susceptibility of bloodstream fungal isolates in

pediatric patients: a Spanish multicenter prospective survey / J. Pemán, E. Cantón,

five hospitals in the UK. / C. Chalmers, S. Gaur, J. Chew, et al. // Journal of

Mycoses. – 2011. – Vol. 54. – Suppl. 6. – P. 795–800.

97.Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry / D. L. Horn, D. Neofytos, E. J. Anaissie, et al. // World Journal of Clinical Infectious Diseases. – 2009. – Vol. 48. – P. 1695–1703.

98.Epidemiology and outcomes of candiemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. / M. A. Pfaller, D. Neofytos, D. Diekema, et al. // Journal Diagnostic Microbiology and Infectious Disease. – 2012. – Vol. 74. – Suppl. 4. – P. 323–331.

99.Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. / B. Almirante, D. Rodriguez, B. J. Park, M. Cuenca–Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, P. Sabolls, S. K. Fridkin, J. Morgan, J. L. Rodriguez–Tudela, D. W. Warnock, A. Pahissa, and the Barcelona Candidemia Project Study Group // Journal of Clinical Microbiology. –

2005. – Vol. 43. – Р. 1829–1835

100. Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project) Infection. / M. T. Montagna, G. Caggiano, G. Lovero, et al. / Journal of Infectious. – 2013. – Vol. 41. – Suppl. 3. – P. 645–653.

101. Epidemiology of opportunistic fungal infections in Latin America / M. Nucci, F.

Queiroz–Telles, A. M. Tobón, A. Restrepo, A. L. Colombo // European Journal of

Clinical Microbiology & Infectious Diseases. – 2010. – Vol. 51. – Suppl. 5. – P.

561–570.

102. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case–control population-based surveillance study of patients in

Estrella, et al. // Journal of Clinical Microbiology. – 2006. – Vol. 44. – P. 1681–

1685.

103. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. / G. L. Macphail, G. D. Taylor, M. Buchanan–Chell, C. Ross, S. Wilson, A. Kureishi // Journal of Mycoses. – 2002. – Vol. 45. – Suppl. 5–6. – P.

141–145.

104. Eggimann, P. Epidemiology of Candida species infections in critically ill non- immunosuppressed patients. / P. Eggimann, J. Garbino, D. Pittet. // Journal of Lan- cet Infection Diseases. – 2003. – Vol. 3. – Р. 685–702.

105. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. / O. A. Cornely, M. Bassetti, T. Calandra, et al. // Journal of Clinical Microbiology and Infection. – 2012. – Vol. 18. – Suppl. 7. – P.

19–37.

106. European expert opinion on the management of invasive candidiasis in adults / B.

J. Kullberg, P. E. Verweij, M. Akova, et al. // Journal of Clinical Microbiology and

Infection. – 2011. – Vol. 17, Suppl. 5. – P. 1–12. – 2008. – Vol. 106. – P. 523–529.

107. Evaluation of species distribution and risk factors of candidemia: a multicenter case–control study / N. Yapar, H. Pullukcu, V. Avkan–Oguz, et al. // Journal Medical Mycology. – 2011. – Vol. 49. – Suppl. 1. – P. 26–31.

108. Excess mortality, hospital stay, and cost due to candidemia: a case–control study using data from population-based candidemia surveillance. / J. Morgan, M. I. Meltzer, B. D. Plikaytis, A. N. Sofair, S. Huie–White, S. Wilcox, L. H. Harrison, E. C. Seaberg, R. A. Hajjeh, S. M. Teutsch. // Journal Infection Control and Hospital Epidemiology. – 2005. – Vol. 26. – Р. 540–547.

109. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infectons: a reappraisal. / M. Garrouste–Orgeas, J. F. Timsit, M. Tafflet, V. Misset, J. R. Zahar, L. Soufir, T. Lazard, S. Jamali, B. Mourvillier, Y. Cohen, A. DeLassence, E. Azoulay, C. Cheval, A. Descrops–Declere, C. Adrie, M. A. Costade

Beuregard, J. Corlet. // Journal Clinical Infection Diseases. – 2006. – Vol. 42. – Р.

1118–1126.

110. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study / D. H. Kett, E. Azoulay, P. M. Echeverria, J. L. Vincent // Journal Critical Care Medicine. – 2011. – Vol. 39. – Suppl. 4. – P. 665–670.

111. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit / J. K. Chow, Y. Golan, R. Ruthazer, et al. // World Journal of Clinical Infectious Diseases. – 2008. – Vol. 46. – P. 1206–1213.

112. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit / J. K. Chow, Y. Golan, R. Ruthazer, et al. // World Journal of Clinical Infectious Diseases. – 2008. – Vol. 46. – Suppl. 8. –P. 1206–1213.

113. Factors associated with candiduria and related mortality / N. Paul, E. Mathai, O.

C. Abraham, J. S. Michael, D. Mathai // Journal Infectious. – 2007. – Vol. 55. –

Suppl. 5. – P. 450–455.

114. Factors determining visual outcome in endogenous Candida endophthalmitis / A.

Sallam, S. R. Taylor, A. Khan, P. McCluskey, W. A. Lynn, K. Manku, et al. // The

Journal of Retinal and Vitreous Diseases. – 2012. – Vol. 32. – Suppl. 6. – Р. 1129–

1134.

115. Falagas, M. E. Attributable mortality of candidemia: a systematic review of matched cohort and case–control studies / M. E. Falagas, K. E. Apostolou, V. D. Pappas // World Journal of Clinical Infectious Diseases. – 2006. – Vol. 25. – P.

419–425.

116. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients / P. Eggimann, P. Francioli, J. Bille, et al. // Journal of Critical Care Medicine. – 1999. – Vol. 27. – P. 1066–1072.

117. Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan / Y. L.Yang, H. H. Cheng, Y. A. Ho, C. F. Hsiao, H. J. Lo

// Journal of Microbiology, Immunology and Infection. – 2003. – Vol. 36. – Suppl.

3. – P. 187–191.

118. Freemantle, N. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease / N. Freemantle, P. Tharmanathan, R. Herbrecht // Journal of Antimicrobial Chemotherapy. – 2011. – Vol. 66. – Suppl. 1. – P. 25–35.

119. Fungal Infection Network of Switzerland Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. / O. Marchetti, J. Bille, U. Fluckiger, et al. // World Journal of Clinical Infectious Diseases. – 2004. – Vol. 38.

– Suppl. 3. – P. 311–320.

120. Fungal neuroinfections: rare disease but unacceptably high mortality. / S. Njambi, M. Huttova, M. Kovac, et al. // Journal Neuroendocrinology Letters. – 2007. – Vol.

28. – Р. 25–26.

121. Fungemia and Renal Fungus Ball Formation with Candida norvegensis in a Child with Acute Lymphoblastic Leukemia / K. Nilgün, K. Sibel, T. İlknur, E. Erol, K. İftihar // The Turkish Journal of Pediatrics. – 2011. – Vol. 53. – Р. 448–451.

122. FUNGEMYCA Study Group Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey / J. Pemán, E. Cantón, G. Quindós, et al. // Journal of Antimicrobial Chemotherapy. –

2012. – Vol. 67. – Suppl. 5. – P. 1181–1187.

123. Garzoni, C. Candida parapsilosis endocarditis: a comparative review of the literature / C. Garzoni, V. A. Nobre, J. Garbino // European Journal of Clinical Microbiology & Infectious Diseases. – 2007. – Vol. 26. – Suppl. 12. – Р. 915–926.

124. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008–2009). / M. A. Pfaller, G. J. Moet, S. A. Messer, R. N. Jones, M. Castanheira // Journal of Clinical Microbiology. – 2011. – Vol. 49. – Suppl. 1. – P. 396–399.

125. Giri, S. A review of Candida species causing blood stream infection Indian / S.

Giri, A.J. Kindo // Journal of Clinical Microbiology. – 2012. – Vol. 30. – Suppl. 3. – Р. 270–278.

126. Global Antifungal Surveillance Group Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5 year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion / M. A. Pfaller, D. J. Diekema, D. L. Gibbs, et al. // Journal of Clinical Microbiology. – 2010. – Vol. 48. – Suppl. 4. – P. 1366–1377.

127. Gokce, G. Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures / G. Gokce, N. Cerikcioglu, A. Yagci // Journal of Mycopathologia. – 2007. – Vol. 164. – Suppl. 6. – P. 265–269.

128. Hajouz, S. Un cas de bézoard candidosique renal. Renal candidal bezoar: Case report and review of the literature / S. Hajouz, R. Dafiri // Journal Archives de Pédiatrie. – 2014. – Vol. 21. – Suppl. 1. – P. 70–72.

129. Has the epidemiology of nosocomial candidemia changed? / L. Puzniak, S.

Teutsch, W. Powderly, L. Polish. // Journal Infection Control & Hospital Epidemi- ology. – 2004. – Vol. 25. – Р. 628–633.

130. Heintz, B. H. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis / B. H. Heintz, G. R. Matzke, W. E. Dager // Journal Pharmacotherapy. – 2009. – Vol. 29. – P. 562–577.

131. International study of the prevalence and outcomes of infection in intensive care units / J. L.Vincent, J. Rello, J. Marshall, et al. // Journal JAMA. – 2009. – Vol. 302.

– P. 2323–2329.

132. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta- Dglucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis / M. A. Mennink-Kersten, D. Ruegebrink, N. Wasei, et al. // Journal of Clinical Microbiology. – 2006. – Vol. 44. – P. 1711–1718.

133. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized

trials / D. R. Andes, N. Safdar, J. W. Baddley, et al. // World Journal of Clinical

Infectious Diseases. – 2012. – Vol. 54. – P. 1110–1122.